Mehdi Afshar1, George Thanassoulis. 1. aDepartment of Medicine, McGill University bPreventive and Genomic Cardiology, McGill University Health Center and Research Institute cDepartment of Clinical Epidemiology, McGill University Health Center, Montreal, Quebec, Canada.
Abstract
PURPOSE OF REVIEW: Lipoprotein(a) [Lp(a)] is the strongest independent genetic risk factor for both myocardial infarction and aortic stenosis. It has also been associated with other forms of atherosclerotic cardiovascular disease (CVD) including ischemic stroke. Its levels are genetically determined and remain fairly stable throughout life. Elevated Lp(a), above 50 mg/dl, affects one in five individuals worldwide. RECENT FINDINGS: Herein, we review the recent epidemiologic and genetic evidence supporting the causal role of Lp(a) in CVD, highlight recommendations made by European and Canadian guidelines regarding Lp(a) and summarize the rapidly evolving field of Lp(a)-lowering therapies including antisense therapies and Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors. SUMMARY: With novel therapies on the horizon, Lp(a) is poised to gain significant clinical relevance and its lowering could have a significant impact on the burden of CVD. VIDEO ABSTRACT.
PURPOSE OF REVIEW: Lipoprotein(a) [Lp(a)] is the strongest independent genetic risk factor for both myocardial infarction and aortic stenosis. It has also been associated with other forms of atherosclerotic cardiovascular disease (CVD) including ischemic stroke. Its levels are genetically determined and remain fairly stable throughout life. Elevated Lp(a), above 50 mg/dl, affects one in five individuals worldwide. RECENT FINDINGS: Herein, we review the recent epidemiologic and genetic evidence supporting the causal role of Lp(a) in CVD, highlight recommendations made by European and Canadian guidelines regarding Lp(a) and summarize the rapidly evolving field of Lp(a)-lowering therapies including antisense therapies and Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors. SUMMARY: With novel therapies on the horizon, Lp(a) is poised to gain significant clinical relevance and its lowering could have a significant impact on the burden of CVD. VIDEO ABSTRACT.
Authors: Allan D Sniderman; Patrick Couture; Seth S Martin; Jacqueline DeGraaf; Patrick R Lawler; William C Cromwell; John T Wilkins; George Thanassoulis Journal: J Lipid Res Date: 2018-05-16 Impact factor: 5.922
Authors: Natalie Koh; Brian A Ference; Stephen J Nicholls; Ann Marie Navar; Derek P Chew; Karam Kostner; Ben He; Hung Fat Tse; Jamshed Dalal; Anwar Santoso; Junya Ako; Hayato Tada; Jin Joo Park; Mei Lin Ong; Eric Lim; Tavin Subramaniam; Yi-Heng Li; Arintaya Phrommintikul; S S Iyengar; Saumitra Ray; Kyung Woo Park; Hong Chang Tan; Narathip Chunhamaneewat; Khung Keong Yeo; Jack Wei Chieh Tan Journal: Eur Cardiol Date: 2021-12-09
Authors: Mehdi Afshar; Jian Rong; Yang Zhan; Hao Yu Chen; James C Engert; Allan D Sniderman; Martin G Larson; Ramachandran S Vasan; George Thanassoulis Journal: J Am Heart Assoc Date: 2020-09-06 Impact factor: 5.501